Mari GOTOH

Dr. Mari GOTOH

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2012 in Biochemical Society Transactions
Verified
Journal Article
Closed access
PDF file
MGMari GOTOH
Mari GOTOH
YFYuko Fujiwara
Yuko Fujiwara
JYJunming Yue
Junming Yue
JLJianxiong Liu
Jianxiong Liu
SLSueChin Lee
SueChin Lee
GTGabor Tigyi
Gabor Tigyi
LPA (lysophosphatidic acid, 1-acyl-2-hydroxy-sn-glycero-3-phosphate), is a growth factor-like lipid mediator that regulates many cellular functions, many of which are unique to malignantly transformed cells. The simple chemical structure of LPA and its profound effects in cancer cells has attracted the attention of the cancer therapeutics field and drives the development of therapeutics based on the LPA scaffold. In biological fluids, LPA is generated by ATX (autotaxin), a lysophospholipase D that cleaves the choline/serine headgroup from lysophosphatidylcholine and lysophosphatidylserine to generate LPA. In the present article, we review some of the key findings that make the ATX–LPA signalling axis an emerging target for cancer therapy.

1 December 2019 in Brain Research
Verified
Journal Article
Closed access
SNShingo Nakajima
Shingo Nakajima
MGMari GOTOH
Mari GOTOH
KFKeiko Fukasawa
Keiko Fukasawa
KMKimiko Murakami-Murofushi
Kimiko Murakami-Murofushi
HKHiroshi Kunugi
Hiroshi Kunugi

1 June 2003 in Developmental Cell
Verified
Journal Article
Closed access
JNJin Nakahara
Jin Nakahara
KTKyoko Tan-Takeuchi
Kyoko Tan-Takeuchi
CSChika Seiwa
Chika Seiwa
MGMari GOTOH
Mari GOTOH
TKTomonori Kaifu
Tomonori Kaifu
HAHiroaki Asou
Hiroaki Asou

1 October 2010 in Cellular Signalling
Verified
Journal Article
Closed access
WVWilliam J. Valentine
William J. Valentine
GKGyöngyi N. Kiss
Gyöngyi N. Kiss
JLJianxiong Liu
Jianxiong Liu
SEShuyu E
Shuyu E
MGMari GOTOH
Mari GOTOH
GTGabor Tigyi
Gabor Tigyi

21 October 2019 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
SNShingo Nakajima
Shingo Nakajima
KFKeiko Fukasawa
Keiko Fukasawa
MGMari GOTOH
Mari GOTOH
KMKimiko Murakami-Murofushi
Kimiko Murakami-Murofushi
HKHiroshi Kunugi
Hiroshi Kunugi

21 July 2017 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SYShinji Yamamoto
Shinji Yamamoto
KYKota Yamashina
Kota Yamashina
MIMasaki Ishikawa
Masaki Ishikawa
MGMari GOTOH
Mari GOTOH
SYSosuke Yagishita
Sosuke Yagishita
KYKeisuke Yoshikawa
Keisuke Yoshikawa
Multiple sclerosis is a neuroinflammatory demyelinating and neurodegenerative disease of the central nervous system characterized by recurrent and progressive demyelination/remyelination cycles, neuroinflammation, oligodendrocyte loss, demyelination, and axonal degeneration. Cyclic phosphatidic acid (cPA) is a natural phospholipid mediator with a unique cyclic phosphate ring structure at the sn-2 and sn-3 positions of the glycerol backbone. We reported earlier that cPA elicits a neurotrophin-like action and protects hippocampal neurons from ischemia-induced delayed neuronal death. We designed, chemically synthesized, and metabolically stabilized derivatives of cPA: 2-carba-cPA (2ccPA), a synthesized compound in which one of the phosphate oxygen molecules is replaced with a methylene group at the sn-2 position. In the present study, we investigated whether 2ccPA exerts protective effects in oligodendrocytes and suppresses pathology in the two most common mouse models of multiple sclerosis. To evaluate whether 2ccPA has potential beneficial effects on the pathology of multiple sclerosis, we investigated the effects of 2ccPA on oligodendrocyte cell death in vitro and administrated 2ccPA to mouse models of experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced demyelination. We demonstrated that 2ccPA suppressed the CoCl2-induced increase in the Bax/Bcl-2 protein expression ratio and phosphorylation levels of p38MAPK and JNK protein. 2ccPA treatment reduced cuprizone-induced demyelination, microglial activation, NLRP3 inflammasome, and motor dysfunction. Furthermore, 2ccPA treatment reduced autoreactive T cells and macrophages, spinal cord injury, and pathological scores in EAE, the autoimmune multiple sclerosis mouse model. We demonstrated that 2ccPA protected oligodendrocytes via suppression of the mitochondrial apoptosis pathway. Also, we found beneficial effects of 2ccPA in the multiperiod of cuprizone-induced demyelination and the pathology of EAE. These data indicate that 2ccPA may be a promising compound for the development of new drugs to treat demyelinating disease and ameliorate the symptoms of multiple sclerosis.